Psyence Biomedical Ltd.
PBM · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $1 | $2 | $0 |
| G&A Expenses | $0 | $2 | $2 | $2 |
| SG&A Expenses | $3 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$2 | -$2 |
| Operating Expenses | $4 | $3 | $1 | $0 |
| Operating Income | -$4 | -$3 | -$1 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | -$48 | $9 | $9 |
| Pre-Tax Income | $1 | -$51 | $8 | $8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $1 | -$51 | $8 | $8 |
| % Margin | – | – | – | – |
| EPS | 1.78 | -7.85 | -0.64 | 0.25 |
| % Growth | 122.7% | -1,126.6% | -356% | – |
| EPS Diluted | 1.78 | -7.85 | -0.64 | 0.25 |
| Weighted Avg Shares Out | 1 | 7 | 33 | 33 |
| Weighted Avg Shares Out Dil | 1 | 7 | 33 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | -$51 | -$1 | -$0 |
| % Margin | – | – | – | – |